FY2024 EPS Estimates for ZNTL Increased by Leerink Partnrs

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($2.35) per share for the year, up from their previous forecast of ($2.68). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.68) EPS, FY2025 earnings at ($2.01) EPS, FY2026 earnings at ($1.82) EPS and FY2027 earnings at ($1.76) EPS.

Other equities analysts have also recently issued research reports about the company. Wedbush restated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. UBS Group dropped their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. HC Wainwright decreased their price objective on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Wells Fargo & Company dropped their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Finally, Guggenheim lowered their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $1.63 on Monday. Zentalis Pharmaceuticals has a 12 month low of $1.61 and a 12 month high of $18.07. The stock’s 50-day moving average is $2.87 and its two-hundred day moving average is $3.23. The stock has a market cap of $116.16 million, a PE ratio of -0.65 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36.

Insider Activity

In other news, Director Jan Skvarka purchased 60,000 shares of the stock in a transaction dated Friday, January 31st. The shares were bought at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now owns 149,551 shares in the company, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently modified their holdings of ZNTL. Verition Fund Management LLC raised its holdings in Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after buying an additional 951,500 shares in the last quarter. Primecap Management Co. CA raised its position in Zentalis Pharmaceuticals by 21.6% in the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after purchasing an additional 265,690 shares during the last quarter. GSA Capital Partners LLP boosted its stake in Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after acquiring an additional 353,384 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Zentalis Pharmaceuticals by 126.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after purchasing an additional 127,868 shares during the period. Finally, XTX Topco Ltd grew its position in shares of Zentalis Pharmaceuticals by 8.7% in the 3rd quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after purchasing an additional 15,597 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.